CHICAGO TRUST Co NA Buys 17,250 Shares of Pfizer Inc. $PFE

Key Points

• CHICAGO TRUST Co NA increased its stake in Pfizer Inc. by 41%, acquiring an additional 17,250 shares, bringing its total holdings to 59,314 shares worth approximately $1.44 million.
• Recent research reports have resulted in various price objective changes for Pfizer, with Citigroup and Bank of America raising their targets to $26.00 and $28.00 respectively, while Berenberg Bank lowered its target to $25.00.
• Pfizer announced a quarterly dividend of $0.43 per share, paid in September, reflecting an annualized yield of 7.2% and a payout ratio of 91.49%.

CHICAGO TRUST Co NA boosted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 41.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 59,314 shares of the biopharmaceutical company's stock after buying an additional 17,250 shares during the period. CHICAGO TRUST Co NA's holdings in Pfizer were worth $1,438,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the business. Capital Advisory Group Advisory Services LLC increased its position in Pfizer by 2.9% in the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company's stock worth $328,000 after buying an additional 388 shares during the period. Trust Co of the South increased its position in Pfizer by 1.5% in the 2nd quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company's stock worth $712,000 after buying an additional 441 shares during the period. Charter Oak Capital Management LLC increased its position in Pfizer by 4.3% in the 2nd quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company's stock worth $258,000 after buying an additional 444 shares during the period. Members Trust Co increased its position in shares of Pfizer by 2.1% during the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock valued at $587,000 after purchasing an additional 467 shares during the period. Finally, Sutton Place Investors LLC increased its position in shares of Pfizer by 5.6% during the first quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock valued at $224,000 after purchasing an additional 472 shares during the period. 68.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

PFE has been the topic of a number of research reports. Citigroup boosted their price objective on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Bank of America boosted their price objective on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Berenberg Bank lowered their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research report on Thursday, May 29th. Morgan Stanley boosted their price objective on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Finally, Wall Street Zen upgraded Pfizer from a "hold" rating to a "buy" rating in a research report on Saturday. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $28.12.

Pfizer Trading Up 0.1%

Shares of PFE opened at $24.05 on Tuesday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The firm has a market capitalization of $136.74 billion, a PE ratio of 12.79, a price-to-earnings-growth ratio of 0.78 and a beta of 0.55. The stock's fifty day simple moving average is $24.61 and its 200-day simple moving average is $24.18.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the prior year, the firm posted $0.60 earnings per share. The firm's revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.2%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer's dividend payout ratio is 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.